More on BD fiscal Q2 results


Revenues: $2.072B (+3.6%), Medical: $1.116B (+5.1%), Diagnostics: $653M (+0.9%), Biosciences: $302M (+8.2%).

EPS: $1.45 (+4.3%).

Updated F14 guidance:

Revenue growth: 4% - 4.5%.

EPS: $6.14 - $6.17, down from $6.19 - $6.22.

(BDX)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs